Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan

被引:0
作者
Katsutoshi Hiramatsu
Annabel Barrett
Yasuhiko Miyata
机构
[1] Amgen K.K.,
[2] Eli Lilly and Company Limited,undefined
[3] Bristol Myers Squibb K.K.,undefined
来源
Drugs - Real World Outcomes | 2021年 / 8卷
关键词
D O I
暂无
中图分类号
学科分类号
摘要
引用
收藏
页码:459 / 480
页数:21
相关论文
共 145 条
[1]  
Yoneoka D(2014)Are Japanese randomized controlled trials up to the task? A systematic review PLoS One 9 e90127-14
[2]  
Hisashige A(2015)A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results Trials 16 495-865
[3]  
Ota E(2016)Clinicoepidemiological studies using the DPC data: challenges for the future [in Japanese] Iryo To Shakai. 26 7-39
[4]  
Miyamoto K(2012)Comparative study of scientific publications in urology and nephrology journals originating from USA, China and Japan (2001–2010) PLoS ONE 7 e42200-1039
[5]  
Nomura S(2017)What is real-world data? A review of definitions based on literature and stakeholder interviews Value Health. 20 858-2297
[6]  
Segawa M(2019)Real-world data for regulatory decision making: challenges and possible solutions for Europe Clin Pharmacol Ther 106 36-81
[7]  
Kennedy-Martin T(2017)Good practices for real-world data studies of treatment and/or comparative effectiveness: recommendations from the joint ISPOR-ISPE Special Task Force on real-world evidence in health care decision making Pharmacoepidemiol Drug Saf 26 1033-463
[8]  
Curtis S(2016)Real-world evidence—what is it and what can it tell us? N Engl J Med 375 2293-320
[9]  
Faries D(2017)National Clinical Database (NCD) in Japan for gastroenterological surgery: brief introduction Ann Gastroenterol Surg. 1 80-382
[10]  
Robinson S(2019)National Clinical Database (NCD) in Japan: clinical and social significance Ann Gastroenterol Surg. 3 462-2851